COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases (Part 2)
Allow me to continue the discussion that started in our previous column.
There are general considerations when it comes to Covid vaccinations among those with rheumatic and musculoskeletal disease (RMD).
There is no evidence found to back a concern regarding the use or timing of immunomodulatory therapies in relation to vaccine safety.
For this reason, guidance regarding immunomodulatory medication and vaccination timing was given considering the intent to optimize vaccine response.
There is an important set of guiding principles, foundational assumptions and limitations mentioned in studies conducted for this purpose.
The American College of Rheumatology (ACR) is focused on updating this guidance as an evolving when new evidence appears.
The guidelines are important to allow patients to get protection against Covid at the same time shield themselves from possible repercussions or side effects of the inoculation.
It has been observed that the vaccines are important tools to help people get rid of the virus and push the return to normalcy.
The pandemic has shut down the economy and as such we need to go back to normalcy. For this reason, vaccines are important.
In our next column we will be mentioning the recommendations for clinicians in order to handle the administration of Covid vaccines to patients with RMD.